View Older Stories View More Recent Stories

Feb 25, 2025 06:45AM Merck (MRK) Granted FDA Priority Review to Application for KEYTRUDA Plus Standard of Care as Perioperative Treatment for Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma
Feb 24, 2025 02:23PM ROSEN, A GLOBALLY RESPECTED LAW FIRM, Encourages Merck & Co., Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - MRK
Feb 24, 2025 02:10PM MERCK INVESTOR DEADLINE: Robbins Geller Rudman & Dowd LLP Announces that Merck & Co., Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - MRK
Feb 22, 2025 10:17PM ROSEN, A LEADING FIRM, Encourages Merck & Co., Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - MRK
Feb 22, 2025 08:16AM SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Merck & Co.
Feb 22, 2025 04:00AM What's the current state of China's GLP-1 market?
Feb 21, 2025 07:28PM ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Merck & Co., Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - MRK
Feb 21, 2025 04:00PM MRK INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Merck & Co., Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
Feb 20, 2025 11:25AM MRK INVESTOR DEADLINE: Merck & Co., Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
Feb 19, 2025 03:44PM ROSEN, RECOGNIZED INVESTOR RIGHTS COUNSEL, Encourages Merck & Co., Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - MRK
Feb 18, 2025 06:51PM INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Merck & Co.
Feb 18, 2025 04:25PM IVF stocks on watch as President Trump signs an executive order to expand access
Feb 18, 2025 11:40AM Merck And Plaintiff Suing Over Alleged Gardasil Vaccine Injuries Agree To Delay Trial Until September 2025 With New Jury - Reuters
Feb 18, 2025 06:45AM Merck (MRK) Reports WELIREG Received First European Commission Approval for Two Indications
Feb 17, 2025 02:04PM ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Merck & Co., Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - MRK
Feb 16, 2025 04:00PM MRK INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Merck & Co., Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
Feb 15, 2025 09:25PM ROSEN, SKILLED INVESTOR COUNSEL, Encourages Merck & Co., Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - MRK
Feb 15, 2025 09:33AM SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Merck & Co.
Feb 14, 2025 02:30PM ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Merck & Co., Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - MRK
Feb 12, 2025 07:09AM Merck (MRK) PT Lowered to $115 at Guggenheim
Feb 12, 2025 07:02AM Neuphoria (NEUP) to Receive $15M Milestone Payment from Merck
Feb 11, 2025 05:50AM Merck (MRK) PT Lowered to $95 at Bernstein SocGen Group
Feb 10, 2025 05:29AM TD Cowen Downgrades Merck (MRK) to Hold
Feb 6, 2025 06:45AM Merck (MRK) Announces Phase 3 waveLINE-010 Trial Initiation Evaluating Zilovertamab Vedotin
Feb 5, 2025 10:22AM Merck (MRK) PT Lowered to $96 at BMO Capital as 'Gardasil Cut Lowers Confidence'
Feb 5, 2025 06:35AM Merck (MRK) PT Lowered to $129 at Goldman Sachs
Feb 4, 2025 06:31AM Merck (MRK) Misses Q4 EPS by 9c; misses on outlook
Feb 3, 2025 10:37AM Merck (MRK) call put ratio 3.1 calls to 1 put with a focus on February 7 weekly 100 calls
Feb 3, 2025 05:04AM Merck (MRK) call put ratio 2.3 calls to 1 put into quarter results
Jan 31, 2025 10:37AM Merck (MRK) call put ratio 3.1 calls to 1 put with a focus on January 2027 100 calls
Jan 31, 2025 06:45AM Merck (MRK) Receives Positive EU CHMP Opinion for CAPVAXIVE
Jan 31, 2025 05:16AM Merck (MRK) February 7 weekly 99 straddle priced into quarter results
Jan 30, 2025 06:45AM Merck (MRK) to Stop Phase 3 HYPERION Trial Evaluating WINREVAIR Early and Move to Final Analysis
Jan 28, 2025 01:28PM Merck (MRK) Declares $0.81 Quarterly Dividend; 3.3% Yield
Jan 28, 2025 01:28PM Merck (MRK) Announces $10B Share Buyback
Jan 24, 2025 06:45AM Merck (MRK) and Eisai Provide Update on Phase 3 LEAP-015 Trial Evaluating KEYTRUDA Plus LENVIMA in Combination with Chemotherapy
Jan 17, 2025 07:11AM Merck (MRK) PT Lowered to $122 at Guggenheim
Jan 13, 2025 11:14AM Bernstein Weighs in on US Biopharma Sector in 2025; Highlights LLY as Top-pick
Jan 8, 2025 06:48AM Merck's (MRK) GARDASIL Receives Expanded Approval for Males in China
Jan 7, 2025 11:00AM TD Cowen on Pharma: '10 Events in 2025 That Could Change Practice, Alter Companies, Move Stocks'
Jan 2, 2025 12:39PM TD Cowen on Trump Tariffs and Other Risks: 'Where Does Pharma Stand?'
Dec 20, 2024 06:45AM Merck (MRK) Closes Exclusive Global License Agreement for LM-299
Dec 20, 2024 04:09AM BMO Capital Downgrades Merck (MRK) to Market Perform
Dec 19, 2024 07:34AM Merck (MRK) 'Buys' GLP-1 (HS-10535) From China; Bernstein Reiterates Market Perform Rating
Dec 19, 2024 06:45AM Merck (MRK) Announces Topline Results from Pivotal Phase 3 Trials Evaluating Investigational, Once-Daily, Oral, Two-Drug, Single-Tablet Regimen of Doravirine/Islatravir
Dec 18, 2024 08:20AM BMO Capital on Merck's obesity deal (MRK): 'transaction likely viewed as positive, but Merck would have been better served going after later-stage development'
Dec 18, 2024 07:51AM Viking Therapeutics (VKTX) weakness tied to Merck's (MRK) Deal for GLP-1 Receptor Agonist
Dec 18, 2024 06:45AM Merck (MRK) Enters into Exclusive Global License Agreement with Hansoh Pharma for Investigational Oral GLP-1 Receptor Agonist
Dec 17, 2024 06:49AM Bernstein SocGen Group Reiterates Market Perform Rating on Merck (MRK)
Dec 17, 2024 06:46AM Merck (MRK) Announces FDA Acceptance of BLA for Clesrovimab
View More Recent Stories View Older Stories